Actively Recruiting

Age: 18Years +
All Genders
NCT06822829

Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma

Led by Azienda USL Reggio Emilia - IRCCS · Updated on 2026-05-05

50

Participants Needed

1

Research Sites

101 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Most relapses of diffuse large B-cell lymphoma (DLBCL) occur as high-grade lymphoma within the first two years after diagnosis. Relapses as indolent lymphoma are rare events, and the true incidence of this phenomenon is unknown, since literature data are scarce/ and usually restricted to case reports. Analogously, reported treatment strategies are rather heterogeneous, since no standard of care is established and advanced age together with previous anthracycline exposure may narrow the therapeutic choice. The goal of this observational study is to assess epidemiological, clinical characteristics and survival of diffuse large b-cell lymphoma (DLBCL) relapsing as indolent lymphoma. More precisely, the study aims at identifying diagnostic and imaging features associated with relapse as indolent lymphoma and at evaluating disease response to selected therapies.

CONDITIONS

Official Title

Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older at the time of diagnosis.
  • Previous diagnosis of diffuse large B-cell lymphoma with or without an indolent B-cell lymphoma component, or DLBCL transformed from indolent B-cell lymphoma.
  • First-line treatment for diffuse large B-cell lymphoma.
  • Histologically confirmed relapse of indolent B-cell lymphoma diagnosed between 2010 and 2020.
  • Availability of histological report of the relapse.
  • Availability of clinical and laboratory data from both initial diagnosis and relapse.
  • Availability of follow-up data.
  • Consent to participate and signed informed consent form (for living and/or contactable patients).
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Azienda USL IRCCS di Reggio Emilia

Reggio Emilia, Italy

Actively Recruiting

Loading map...

Research Team

A

Attilio Gennaro, Clinical Research Coordinator

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here